en · de · es
sr9009-notes.peptides7501.com › Blog › Background And Receptor Mechanism — Questions and Answers

Background And Receptor Mechanism — Questions and Answers

By Editorial Desk · published 2025-07-18 · last reviewed 2025-08-15 · Blog

The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-08-15 and is reviewed periodically as new material appears.

Background and Receptor Mechanism

At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.

Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.

Regulation, Testing, and Storage

SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.

Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.

Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic small moleculeStudied as a REV-ERB agonist
Molecular formulaC20H24ClN3O4SReported for the neutral compound
AppearanceOff-white to pale yellow solidTypical research-grade material
SolubilitySparingly soluble in waterSoluble in solvents such as DMSO
Common synonymsSR9009; StenabolicStenabolic is an informal alias

Background and Mechanism

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.

At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.

Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.

Related pages on this site

Analytical and Handling Considerations

Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.

SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.

Supporting material

206Pb(48Ca,xn)254−xNo (x=1,2,3,4) The measurement of the 1-4n excitation functions for this reaction were reported in 2001 by Yuri Oganessian and co-workers at the FLNR. The 2n channel was further studied by the GSI to provide a spectroscopic determination of K-isomerism in 252No. A K-isomer with spin and parity 8− was detected with a half-life of 110 ms.

Even a small, underdeveloped rattle early in the evolution of the rattling system could have been advantageous if tail vibration was an ancestral behavior. At birth, a "prebutton" is present at the tip of the snake's tail; it is replaced by the "button" several days later when the first skin is shed. However, no sound can be made by the rattle until a second segment is added when the skin is shed again. A new rattle segment is added each time the snake sheds its skin, and the snake may shed its skin several times a year, depending on food supply and growth rate. Rattlesnakes travel with their rattles held up to protect them from damage, but in spite of this precaution, their day-to-day activities in the wild still cause them to regularly break off end segments. Because of this, the number of rattles on its tail is not related to the age of a rattlesnake. Compared to females, males have thicker and longer tails (because they contain the inverted hemipenes). Also, the tails of males taper gradually from the body, whereas the tails of females narrow abruptly at the vent.

=== Commander in Sichuan === After graduation, Liu Wenhui returned to Sichuan. There, Liu rejected an offer by fellow Baoding graduate Deng Xihou to serve under him. Instead, he met with his older nephew Liu Xiang, who recommended him to warlord Liu Cunhou of the Sichuan Army. Liu became a staff officer in Liu Cunhou's army, but before long, he had been transferred by Liu Xiang to the Eighth Division under General Chen Hongfan, stationed in Leshan. He was promoted rapidly from battalion commander to brigade commander over a period of five years from 1917 to 1922 due to the patronage of Liu Xiang. By 1919, he, along with his close friend Leng Yindong commanded around half of Chen's forces. His performance in the 1919-20 war to expel Yunnanese forces from Sichuan earned him the attention of Liu Chengxun, who promoted him. This caused tensions with Chen Hongfan, and Liu was subsequently forced to flee to Qingshen. The two would later reconcile, and Chen appointed Liu as a commander in the Yibin area. Yibin, at the confluence of the Jinsha and Min rivers, was known as a major trade port. Around the time of the anti-Yunnan campaign, Liu's parents died, and Liu was unable to return home for their funerals. In 1922, Liu Wenhui became a brigade commander at Yibin with his nephew Liu Xiang's help. This move gave him total control over the city. To collect more funds, Liu brought in his brother, Liu Wencai, as an economic official.

Sources: en.wikipedia.org

Notes from published material

Meanwhile, the Prince and Princess of Wales release a monochrome photograph of them and their children: Prince George of Wales, Princess Charlotte of Wales, and Prince Louis of Wales. 10 December Lawyers on the right of the Conservative Party describe the new Rwanda legislation as not "sufficiently watertight". In his first broadcast since leaving the post of Immigration Minister, Robert Jenrick tells the BBC Sunak's draft Rwanda law unlikely to work since it is "weak" and will become "bogged down" in legal challenges. The skull of a pliosaur is discovered off the coast of Dorset. The 2 m (6 ft 7 in) fossil is said to have roamed the waters 150 million years ago. A David Attenborough documentary is scheduled to air on BBC One on New Year's Day revealing the "risky mission" of unearthing the "T-Rex of the seas". 11 December The National Crime Agency (NCA) suggests that street drugs stronger than heroin are linked to the deaths of at least 54 people in the past six months, with 40 more cases awaiting further testing. The UK government is offering a £2.5bn financial package for the return of a Stormont Executive, which includes funds to settle public sector disputes and for public services. 12 December The UK government's Safety of Rwanda (Asylum and Immigration) Bill, a piece of emergency legislation to support the Rwanda asylum plan, passes with a majority of 44 as MPs vote 313–269 in favour of it. Dorset Police are investigating following the death of an asylum seeker, thought to have taken his own life, on the accommodation barge Bibby Stockholm.

=== Drug discovery === One major outcome of research on human genes and proteins has been the identification of potential new drugs for the treatment of disease. This process relies on genome and proteome information to identify proteins associated with specific diseases, which can then be evaluated as therapeutic targets using computational approaches. For example, when a protein is implicated in a disease, knowledge of its three-dimensional structure can guide the design of drugs that interfere with its function. A molecule that fits into the active site of an enzyme but cannot be released can effectively inactivate the enzyme. This principle underlies many modern drug-discovery strategies, which aim to identify compounds capable of modulating or inhibiting disease-relevant proteins. As genetic differences among individuals are increasingly characterized, these approaches are expected to support the development of personalized medicines tailored to improve efficacy for individual patients. A branch of proteomics known as chemoproteomics provides a broad set of tools and techniques for identifying and characterizing the protein targets of drugs, thereby supporting drug discovery and development efforts.

"there are still uncertainties in the risk assessment that could not be completely eliminated by the German Mobile Telecommunication Research Program, in particular possible health risks of long-term exposure to high-frequency electromagnetic fields from cell phone calls in adults (intensive cell phone use over more than 10 years) and the question of whether the use of cell phones by children could have an effect on health. For these reasons, the Federal Office for Radiation Protection still considers preventive health protection (precaution) to be necessary: exposure to electromagnetic fields should be kept as low as possible."

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.

Is SR9009 a SARM?

No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.

What human data exist for SR9009?

Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.

Is SR9009 legal?

Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.

Network